Posted on

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain

Tumor growth within bone is associated with moderate to severe pain. Pain is the most feared consequence of cancer and greatly diminishes the patient’s quality of life.5,34 Mu opioid receptor (MOR)-mediated drugs such as morphine and fentanyl remain the gold standard for the treatment of moderate to severe cancer pain including ongoing and breakthrough cancer pain.1 However, the severity of cancer pain generally requires high doses, and sustained treatment leads to tolerance, which leads to dose escalation.

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain

Orginally Published At: Pain Journal

Leave a Reply

Your email address will not be published. Required fields are marked *